Cyclin-Dependent Kinase Inhibitor p16
"Cyclin-Dependent Kinase Inhibitor p16" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.
| Descriptor ID |
D019941
|
| MeSH Number(s) |
D12.644.360.225.200 D12.776.167.187.200 D12.776.476.225.200 D12.776.624.776.355.200
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p16- Cyclin-Dependent Kinase Inhibitor p16
- Cyclin Dependent Kinase Inhibitor p16
- CDKN2 Protein
- CDKN2A Protein
- MTS1 Protein
- p16INK4 Protein
- p16(INK4A)
- INK4A Protein
- Protein, INK4A
- Cyclin-Dependent Kinase Inhibitor-2A
- Cyclin Dependent Kinase Inhibitor 2A
- Multiple Tumor Suppressor-1
- Multiple Tumor Suppressor 1
- Cdk4-Associated Protein p16
- Cdk4 Associated Protein p16
- p16INK4A Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p16".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p16".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p16" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 4 | 4 |
| 1996 | 1 | 2 | 3 |
| 1998 | 2 | 0 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 2 | 0 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 2 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 3 | 2 | 5 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 4 | 5 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in Profiles.
-
Incidence and Clinicopathologic Characteristics of Human Papillomavirus-independent Invasive Squamous Cell Carcinomas of the Cervix: A Morphologic, Immunohistochemical, and Human Papilloma-Virologic Study of 670 Cases. Am J Surg Pathol. 2023 12 01; 47(12):1376-1389.
-
Programmed Death Ligand-1 Combined Positive Score Concordance and Interrater Reliability in Primary Tumors and Synchronous Lymph Node Metastases in Resected Cases of p16+ Oropharyngeal Squamous Cell Carcinoma. Arch Pathol Lab Med. 2023 04 01; 147(4):442-450.
-
Overview of Ancillary Techniques in Cervical Cytology. Acta Cytol. 2023; 67(2):119-128.
-
Methyltransferase Inhibition Enables Tgfß Driven Induction of CDKN2A and B in Cancer Cells. Mol Cell Biol. 2023; 43(3):115-129.
-
Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report. J Otolaryngol Head Neck Surg. 2022 Feb 05; 51(1):5.
-
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
-
Molecular determinants of response to PD-L1 blockade across tumor types. Nat Commun. 2021 06 25; 12(1):3969.
-
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion. Cancer Res. 2020 11 01; 80(21):4707-4719.
-
Metastatic HPV-Associated Oropharyngeal Versus Primary Pulmonary Squamous Cell Carcinoma: is p16 Immunostain Useful? Head Neck Pathol. 2020 Dec; 14(4):966-973.
-
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020 08; 59(8):484-494.